Exercise Training for Blood Cancers Survivorship
(S-POP Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests how 12 weeks of exercise, including high-intensity interval training (HIIT) and resistance training, can improve health in individuals who have undergone a stem cell transplant for blood cancer. It also examines the exercise's impact on caregivers, focusing on their health and challenges. Individuals who have had a stem cell transplant and their caregivers may be suitable participants if they are approximately three months post-transplant and can safely exercise. As an unphased trial, this study provides a unique opportunity to contribute to understanding the benefits of exercise post-transplant for both patients and caregivers.
Do I need to stop my current medications to join the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that exercise training is safe for patients and caregivers undergoing hematopoietic stem cell transplant?
Research shows that exercise is generally safe for cancer survivors. Studies have found that physical activity plays a crucial role in recovery after a transplant. Exercise not only reduces cancer-related fatigue but also enhances overall well-being. Reviews of research confirm the safety of exercise programs for adults with cancer, with no major issues reported. In fact, exercise often improves health and quality of life for cancer patients.12345
Why are researchers excited about this trial?
Researchers are excited about the exercise training regimen for blood cancer survivorship because it offers a non-pharmaceutical approach to improve overall well-being post-transplant. Unlike traditional treatments that focus solely on medical interventions, this exercise program aims to enhance physical function, cognitive health, and quality of life through structured physical activity. Additionally, it uniquely involves both patients and their caregivers, emphasizing a holistic approach to recovery and support. By incorporating assessments of social support and financial status, researchers hope to gain a comprehensive understanding of survivorship, potentially transforming post-transplant care.
What evidence suggests that exercise training is effective for blood cancer survivorship?
Research has shown that exercise can greatly aid people recovering from blood cancers. It strengthens the body, reduces fatigue, and enhances overall quality of life. Studies have found that exercise can also lower the risk of cancer recurrence and might even surpass some medicines in effectiveness for prevention. In this trial, participants, including both post-allogeneic hematopoietic stem cell transplant patients and their caregivers, will complete 12 weeks of exercise training. For those who have undergone a stem cell transplant, exercise has been linked to better physical health and shorter hospital stays. Overall, exercise is generally safe and can improve mental health and reduce depression in cancer survivors.16789
Who Is on the Research Team?
Chenyu Lin, MD
Principal Investigator
Duke University
Are You a Good Fit for This Trial?
This trial is for English-speaking adults over 18 who have had a hematopoietic stem cell transplant (HCT) within the last 60 to 120 days, as well as their caregivers. It's designed to help improve various aspects of health post-transplant.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo 12 weeks of high-intensity interval training (HIIT) and resistance training to improve physical and cognitive function, mental health, and quality of life
Follow-up
Participants are monitored for changes in physical function, mental health, and quality of life post-intervention
What Are the Treatments Tested in This Trial?
Interventions
- Exercise training
Find a Clinic Near You
Who Is Running the Clinical Trial?
Duke University
Lead Sponsor